Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
about
Recombinant Newcastle disease virus as a vaccine vector for cancer therapyCancer therapy using a self-replicating RNA vaccineImmunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme BTargeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy.Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraUtility of Clostridium difficile toxin B for inducing anti-tumor immunity.Prolonged induction activates Cebpα independent adipogenesis in NIH/3T3 cells.Assumptions of the tumor 'escape' hypothesis.Stimulation of anti-tumor immunity by photodynamic therapyType I Interferons are essential for the efficacy of replicase-based DNA vaccines.Cancer vaccines: progress reveals new complexities.Development of a clinically-precise mouse model of rectal cancer.Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis.Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.Creating therapeutic cancer vaccines: notes from the battlefieldActivating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive Factor.Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigenDeveloping recombinant and synthetic vaccines for the treatment of melanoma.The new vaccines: building viruses that elicit antitumor immunity.Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccineCytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicleEvaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanomaA Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsTumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastasesDendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cellsCutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
P2860
Q24602728-4BD31BDD-9116-4C80-B563-223FF6B29D73Q27481056-39E34441-AA1C-4F25-A22F-358B029F4D4DQ28729023-459F967E-D83A-485F-9610-2E1DAC4EF9ACQ30497901-6E152221-7E97-4974-998F-C38AFD1AE22CQ30584571-B20E48E1-2850-42BD-BB97-3A6545A15B13Q30769959-AD5F8528-586D-477D-A7BF-6CDBFE0CC0F1Q33847896-D4BF850E-99C1-4F85-AD2C-547BF3D9375BQ33935092-522E7A1F-0C4B-428E-8F9D-70192B96E2C0Q34395494-C5561B5D-05FF-4A5A-87CE-D7019F44DBD4Q34550865-0A4703DB-2EB2-471C-88CE-E30E330B7F6BQ34583258-B7896ACC-098B-4C95-B23C-F17D4DED61FAQ34697795-B387A795-A722-4D65-BCC9-38D1D306F0D5Q34705057-2C7CD1A8-064B-4B1A-B7E0-F3E6C3CAE8BDQ34774541-C7FFC262-28D0-4FDF-9616-E6D5DF2DFF5CQ35050485-C32F18A5-A9D8-4BFF-8816-BB418826E2CAQ35092790-12EFA081-9918-43A2-8F17-4BBF87F5ACF5Q35159565-6753C06F-1A04-4835-BE63-C7C55C905384Q35190925-410E157E-50FC-486D-81D2-410A70580CF9Q35575688-BF7F4BEC-50DE-4FB0-A5B0-4BE03F0C092CQ35840578-9F99068A-1E0D-4C75-891D-FD6544FD9388Q35945206-355FF74E-AB7A-4887-AF25-6C8920D64B18Q35946196-38DCEB8E-0F5F-4533-9EE1-2E20BF0686B5Q35946203-86758898-47DB-4902-BE8A-DFCAB40C42EEQ35946213-B5364A24-F58C-4EAA-8C4C-64706D75E6B7Q35948302-7BB2E7BA-6375-4DBB-93F2-3DF3CFAA44AEQ35950374-BF6E3766-ABBE-458B-A834-03AE853DC363Q36014043-D9FD47A2-FEBC-4158-AA72-09FE3DFBDBAAQ36082419-944DE013-6182-40C2-B494-0C16B379E4F9Q36088999-E9AE6E8C-AEEC-4615-92EB-2B8FB5F06016Q36091993-1A4D25FD-4C11-43FE-83EE-52F54C1FD82BQ36223305-08B02B25-87DE-48D1-AB41-090CED565E23Q36294815-CCD8EF83-911A-48DF-AA20-D7D4289E214DQ36322371-DA8069DD-A1F9-4431-8613-98FA517812C6Q36371632-7542D255-AF8F-4C9F-A787-933B67FA5EC2Q36380718-3D192B88-3431-42D8-BA1F-E992F9EC1167Q36380749-8C3DB18D-CBC4-4D8D-B717-E1A1D9432E61Q36404025-E544587F-ABC4-47B3-8401-0DC3AA2F613EQ36432026-2BAA11A2-47B7-4468-A9DD-3AFBB9EC4780Q36454468-9FC2D9AC-612D-4B94-A87B-0BCA33BBBBCCQ36454472-68D7B5E9-7E56-4A33-B022-BB4EF9B6E0DF
P2860
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@ast
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@en
type
label
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@ast
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@en
prefLabel
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@ast
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@en
P2093
P2860
P1476
Active immunotherapy of cancer ...... odel tumor-associated antigen.
@en
P2093
D Panicali
N P Restifo
S A Rosenberg
P2860
P304
P407
P577
1995-05-01T00:00:00Z